Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2018
Pharmacy Choice - News - Generic Drugs - October 20, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/30/17 - Biosimilar medicines could drive down costs, increase access to care for New Jersey residents Biosimilars could drive down costs, increase access to care in NJ, says Stacie Phan
For New Jersey, where nearly one in three people say their health care costs are unreasonable, a robust biosimilars marketplace could have enormous benefits for residents in need of care while reining in ever-increasing health care spending. While most residents of New Jersey may be unfamiliar with the term "biosimilars," they are commonly used thr
12/30/17 - DRAP completing free process of digital listing of all registered drugs
Drug Regulatory Authority said Division of Pharmaceutical Evaluation and Registration, DRAP completing free the process of digital listing of all registered drugs and in this aspect a provisional database has been uploaded on the official website of DRAP. The Authority has initiated the process early in this year for computerization of decades old.
12/30/17 - DRAP starts digital listing of registered drugs
The Drug Regularity Authority of Pakistan has started digital listing of the registered drugs to maintain updated data. The statement issued by DRAP here Friday stated that around sixty thousand medicines would be registered and uploaded on the official website of the authority. The statement said the process of computerisation has been initiated f
12/30/17 - DRAP starts digital listing of registered drugs - Press Note issued by Press Information Department
Following is the text of press note issued by Press Information Department. Drug Regulatory Authority said Division of Pharmaceutical Evaluation and Registration, DRAP completing free the process of digital listing of all registered drugs and in this aspect a provisional database has been uploaded on the official website of DRAP. The Authority has.
12/30/17 - Mylan-Biocon`s breast cancer biosimilar gets ANVISA nod [Sport360]
In a regulatory filing, Biocon said this is the first biosimilar trastuzumab to be approved in Brazil. Commenting on the development, Biocon CEO and Joint Managing Director Arun Chandavarkar said: "Cancer patients in India and some emerging markets have benefited with our trastuzumab and the approval in Brazil will enable affordable access to this
12/30/17 - Supply And Delivery Of Rituximab, Biosimilar For The Centers For The Fight Against Cancer (clcc) [TendersInfo (India)]
Contract notice: supply and delivery of rituximab, biosimilar for the centers for the fight against cancer. Time limit for receipt of tenders or requests to participate: date: 22/01/2018 Local time: 12:00. Conditions for opening tenders date: 22/01/2018 local time: 12:30 Major organization: UNICANCER ACHATS Address: 101 Rue De Tolbiac Paris Cedex 1
12/29/17 - Alkem Labs gets USFDA nod for Triamcinolone Acetonide topical cream [India Infoline News Service]
Alkem Labs has received USFDA nod for its abbreviated new drug application, Triamcinolone Acetonide topical cream. Alkem Labs' US business contributed 16.5% to its total sales in Q2FY18. Alkem Laboratories Ltd is currently trading at Rs2218.9, up by Rs32.95 or 1.51% from its previous closing of Rs2185.95 on the BSE.
12/29/17 - ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
ANI Pharmaceuticals, Inc. today announced that it has acquired the NDAs and U.S. rights to market ATACAND , ATACAND HCT , ARIMIDEX , and CASODEX from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones. AstraZeneca will continue to market and supply ATACAND , ATACAND HCT , ARIMIDEX , and CASODEX outside
12/29/17 - Biocon And Mylan's Biosimilar Trastuzumab Gets Approval In Brazil
CANONSBURG- Biosimilar Trastuzumab, co-developed by Biocon Ltd. and Mylan N.V., has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica, a leading Brazilian pharmaceutical company. Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for t
12/29/17 - Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017/ PRNewswire/ Biosimilar Trastuzumab, co-developed by Biocon Ltd. and Mylan N.V., has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica, a leading Brazilian pharmaceutical company. Co-developed by Biocon and Myla
12/29/17 - Dr. Reddy's Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market
Hyderabad, India and Princeton, NJ, USA- Dr. Reddy's Laboratories Ltd announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran for Injection in the United States market approved by the U.S. Food and Drug Administration. The Alkeran brand and generic had U.S. sales of approximate
12/29/17 - Elorac, Inc. to Market a New Low-Cost Line of Sodium Sulfacetamide/Sulfur Topical Products
By a News Reporter-Staff News Editor at Drug Week Elorac, Inc. announced that it plans to introduce a low-cost line of generic sodium sulfacetamide/sulfur topical formulations for the treatment of acne, rosacea and seborrheic dermatitis. About Elorac, Inc. Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the developm
12/29/17 - Endo to Participate at the 36th Annual J.P. Morgan Healthcare Conference
DUBLIN- Endo International plc announced today that Paul Campanelli, President and CEO, will participate in a fireside chat at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 10:30 a.m. PST/ 1:30 p.m. EST. Endo International plc is a highly focused generics and specialty branded pharmaceutical compan
12/29/17 - Forecast and Analysis on Ethical Pharmaceuticals Market for Period 2014 - 2020
Albany, NY 12/29/2017 Ethical pharmaceuticals or prescription drugs are those licensed drugs that are regulated by various legislations to require a written medical prescription before it can be procured. According to the American Cancer Society, in 2013, approximately 1,660, 290 new cases of cancer were identified and diagnosed in the U.S. A
12/29/17 - Fosun's biosimilar unit to raise $190M
On Dec. 20, Shanghai Henlius Biotech Inc. said it will raise RMB1.3 billion through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company Fosun Pharmaceutical Group Co. Ltd., and other existing investors. Shanghai Henlius, a JV between Fosun and Henlius Biotech Co. Ltd., is developing biosimilar and novel
12/29/17 - Lupin gets USFDA nod for generic psoriasis treatment solution [Arab Times (Kuwait)]
Pharma major Lupin Ltd today said it has received final approval from the US health regulator for its generic version of Dovonex scalp solution used in treatment of psoriasis of scalp. The approval by the US Food and Drug Administration to Lupin`s calcipotriene topical solution is for strength of 0.005 per cent, the company said in a statement.
12/29/17 - Lupin receives USFDA nod for Calcipotriene Topical Solution, generic of Dovonex Scalp solution [India Infoline News Service]
Lupin, through its filing on BSE, has informed that it has received final approval for its Calcipotriene Topical Solution, 0.005% from the United States Food and Drug Administration to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.. Lupin s Calcipotriene Topical Solution, 0.005% is the AT rated gen
12/29/17 - Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace Cream
HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2017/ PRNewswire/ Global pharmaceutical leader Mylan N.V. today announced the U.S. launch of Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan's Estrace Cream. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application
12/29/17 - Sun Pharma Announces US FDA Acceptance of NDA for OTX-101
Mumbai, India- Sun Pharmaceutical Industries Ltd. announces that the US FDA has accepted a New Drug Application, filed by its wholly owned subsidiary, for OTX-101 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in a clear, preservative-free aqueous solution. OTX-101 is now under review for approval by the US FDA, marking an importan
12/29/17 - Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences
Although the threat of biosimilars looms large on the Biotechnology sector, a further boost in performance from the sector is expected in 2018, according a Zacks report. Pre-market, WallStEquities.com monitors Cytokinetics Inc., Geron Corp., Achillion Pharmaceuticals Inc., and Calithera Biosciences Inc.. Shares in South San Francisco, California...
12/29/17 - Teva Announces Exclusive Launch of a Generic Version of Reyataz in the United States
JERUSALEM- Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of a generic version of Reyataz1 capsules in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending..
12/29/17 - UpScript Offers Teva's Generic of Viagra
By a News Reporter-Staff News Editor at Drug Week This week, UpScript began offering the first generic version of Viagra, manufactured by Teva Pharmaceuticals. Prospective patients will conduct a consultation via telephone or video with one of UpScript's U.S. licensed physicians who will determine if sildenafil is right for them. If a prescriptio
12/28/17 - 'BIOSIMILARS NEED HUGE INVESTMENTS, LONGER TIMELINES'
Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, shared her views on research in biosimilars segment. Biocon was among the forerunners in India to spot the opportunity coming from patent expirations on expensive innovator biologic drugs. Before the final approval from the US FDA for biosimilar Trastuzumab, the drug had to be examined
12/28/17 - Glenmark Pharmaceuticals gets final approval for generic Minastrin1 24 Fe Tablets [India Infoline News Service]
Glenmark Pharmaceuticals has been granted final approval by the United States Food& Drug Administration for Norethindrone Acetateand Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets, 1 mg/20 mcg, the generic version of Minastrin 1 24 Fe Tablets, of Allergan Pharmaceuticals International.
12/28/17 - Lupin receives final approval from USFDA for Calcipotriene Topical Solution [India Infoline News Service]
Lupin, through its filing on BSE, has informed that it has received final approval for its Calcipotriene Topical Solution, 0.005% from the United States Food and Drug Administration to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.. The Company is a significant player in the Cardiovascular, Diabetolog
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415